Literature DB >> 12706534

Amylolytic activity of IgM and IgG antibodies from patients with multiple sclerosis.

Andrew N Saveliev1, Dina R Ivanen, Anna A Kulminskaya, Nadezhda A Ershova, Tat'yana G Kanyshkova, Valentina N Buneva, Alexander S Mogelnitskii, Boris M Doronin, Olga O Favorova, Georgy A Nevinsky, Kirill N Neustroev.   

Abstract

IgG and IgM antibodies from the sera of patients with multiple sclerosis (MS) were found to possess amylolytic activity hydrolyzing alpha-(1-->4)-glucosyl linkages of maltooligosaccharides, glycogen, and several artificial substrates. Individual IgM fractions isolated from 54 analyzed patients with the clinically definite diagnoses of MS had approximately three orders of magnitude higher specific amylolytic activity than that for healthy donors, whereas IgG from only a few patients had high amylolytic activity. Strict criteria were used to prove that the amylolytic activity of IgMs and IgGs is their intrinsic property and is not due to any enzyme contamination. Fab fragments produced from IgM and IgG fractions of the MS patients displayed the same amylolytic activity. IgMs from various patients demonstrated different modes of action in hydrolyzing maltooligosaccharides.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706534     DOI: 10.1016/s0165-2478(03)00042-7

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  16 in total

Review 1.  Antibodies as defensive enzymes.

Authors:  Sudhir Paul; Yasuhiro Nishiyama; Stephanie Planque; Sangeeta Karle; Hiroaki Taguchi; Carl Hanson; Marc E Weksler
Journal:  Springer Semin Immunopathol       Date:  2005-01-05

Review 2.  Autoantibodies with enzymatic properties in human autoimmune diseases.

Authors:  Bharath Wootla; Sébastien Lacroix-Desmazes; Arthur E Warrington; Allan J Bieber; Srini V Kaveri; Moses Rodriguez
Journal:  J Autoimmun       Date:  2011-05-31       Impact factor: 7.094

Review 3.  Catalytic antibodies in healthy humans and patients with autoimmune and viral diseases.

Authors:  G A Nevinsky; Valentina N Buneva
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

4.  Physiological IgM class catalytic antibodies selective for transthyretin amyloid.

Authors:  Stephanie A Planque; Yasuhiro Nishiyama; Mariko Hara; Sari Sonoda; Sarah K Murphy; Kenji Watanabe; Yukie Mitsuda; Eric L Brown; Richard J Massey; Stanley R Primmer; Brian O'Nuallain; Sudhir Paul
Journal:  J Biol Chem       Date:  2014-03-19       Impact factor: 5.157

5.  Comparison of antibodies hydrolyzing myelin basic protein from the cerebrospinal fluid and serum of patients with multiple sclerosis.

Authors:  Visilii B Doronin; Taisiya A Parkhomenko; Massimiliano Castellazzi; Marina Padroni; Michela Pastore; Valentina N Buneva; Enrico Granieri; Georgy A Nevinsky
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

6.  Multiple sites of the cleavage of 21- and 25-mer encephalytogenic oligopeptides corresponding to human myelin basic protein (MBP) by specific anti-MBP antibodies from patients with systemic lupus erythematosus.

Authors:  Anna M Timofeeva; Pavel S Dmitrenok; Ludmila P Konenkova; Valentina N Buneva; Georgy A Nevinsky
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

7.  Affinity and catalytic heterogeneity of polyclonal myelin basic protein-hydrolyzing IgGs from sera of patients with multiple sclerosis.

Authors:  Galina A Legostaeva; Dar'ya I Polosukhina; Anna M Bezuglova; Boris M Doronin; Valentina N Buneva; Georgy A Nevinsky
Journal:  J Cell Mol Med       Date:  2009-03-06       Impact factor: 5.310

8.  Formation of different abzymes in autoimmune-prone MRL-lpr/lpr mice is associated with changes in colony formation of haematopoietic progenitors.

Authors:  Alexandra A Andryushkova; Irina A Kuznetsova; Valentina N Bineva; Ludmila B Toporkova; Ludmila V Sakhno; Marina A Tikhonova; Elena R Chernykh; Irina A Orlovskaya; Georgy A Nevinsky
Journal:  J Cell Mol Med       Date:  2007 May-Jun       Impact factor: 5.310

9.  Comparison of DNA-hydrolyzing antibodies from the cerebrospinal fluid and serum of patients with multiple sclerosis.

Authors:  Taisiya A Parkhomenko; Vasilii B Doronin; Massimiliano Castellazzi; Marina Padroni; Michela Pastore; Valentina N Buneva; Enrico Granieri; Georgy A Nevinsky
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

10.  Comparison of Antibodies with Amylase Activity from Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis.

Authors:  Vasilii B Doronin; Taisiya A Parkhomenko; Massimiliano Castellazzi; Edward Cesnik; Valentina N Buneva; Enrico Granieri; Georgy A Nevinsky
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.